Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 21.08.2026 FEX.LN IE00B8X9NW27 1,388,395.00 USD 161,184,869.85  116.094 jh...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 21.08.2026 QSEP.LN IE000FQ808R5  350,002.00 USD   8,742,529.98   24.979  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 21.08.2026 GMAY.LN IE000P0FL8E3 1,400,002.00 USD  56,920,002.11   40.657  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 21.08.2026 MISL.LN IE000NVDQXE1 4,525,002.00 USD 160,047,976.85   35.370  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 21.08.2026 CHPS.LN IE000KXTLDE2  775,002.00 USD  37,184,246.17   47.980  ...

HERZLIYA, Israel--(BUSINESS WIRE)--Cognyte will showcase its financial crimes investigation technology at the IAFCI International Conference in Nashville, Tennessee, August 25-27....

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durab...

مودون، فرنسا--(BUSINESS WIRE)--أرست هيئة الطيران المدني في سنغافورة (CAAS) عقدًا استراتيجيًا رائدًا على شركة تاليس لتطوير نظام جديد من الجيل القادم لإدارة الحركة الجوية (ATMS)، إلى جانب أنظمة رادارات متطورة لمراقبة الحركة الجوية، بما يمثل محطة محورية في مسيرة تطوير منظومة طيران أكثر كفاءة وسلامة واستدامة. سيستبدل نظام الجيل القادم لإدارة الحركة الجوية (ATMS) النظام الحالي لورادس III بحل توب سكاي – إيه تي سي وان المتطور من شركة تاليس. يتضمَّن المشروع كذلك برنامجًا لنقل المعرفة والخبرات، وذلك من خ...

GREENWICH, Conn.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO), today announced the appointment of Ken West as President and Chief Operating Officer, effective September 1, 2026. West will report to Chief Executive Officer Brad Jacobs and be responsible for QXO’s day-to-day operations. West brings an extensive track record of high-impact operational leadership and driving major business transformations. He joins QXO from Honeywell Technologies, where he most recently served as President and Chief Exe...